Seletalisib manufacturers
- Seletalisib
-
- $52.00
-
2026-07-27
- CAS:1362850-20-1
- Purity: 99.81%
- Supply Ability: 10g
|
| | Seletalisib Basic information |
| Product Name: | Seletalisib | | Synonyms: | Seletalisib;Pyrido[3,2-d]pyrimidin-4-amine, N-[(1R)-1-[8-chloro-2-(1-oxido-3-pyridinyl)-3-quinolinyl]-2,2,2-trifluoroethyl]-;UCB-5857;UCB5857;UCB5857; UCB-5857; UCB 5857;Seletalisib(UCB-5857);UCB5857;Inhibitor,Phosphoinositide 3-kinase,Seletalisib,UCB-5857,UCB 5857,inhibit,PI3K;(R)-3-(8-Chloro-3-(2,2,2-trifluoro-1-(pyrido[3,2-d]pyrimidin-4-ylamino)ethyl)quinolin-2-yl)pyridine 1-oxide | | CAS: | 1362850-20-1 | | MF: | C23H14ClF3N6O | | MW: | 482.85 | | EINECS: | | | Product Categories: | | | Mol File: | 1362850-20-1.mol |  |
| | Seletalisib Chemical Properties |
| Boiling point | 710.8±60.0 °C(Predicted) | | density | 1.53±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : ≥ 83.3 mg/mL (172.52 mM) | | form | Solid | | pka | 3.55±0.30(Predicted) | | color | White to off-white |
| | Seletalisib Usage And Synthesis |
| Uses | Seletalisib (UCB5857) is potent and selective PI3Kδ inhibitor with an IC50 of 12 nM. | | in vivo | Seletalisib significantly inhibits IL-2 release following TCR stimulation in the rat. The inhibition is observed at all tested doses of seletalisib with almost complete inhibition reached at dose levels ≥1 mg/kg. Seletalisib has potent in vivo effects with an estimated IC50 value of <10 nM[1]. | | IC 50 | PI3Kδ: 12 nM (IC50) | | References | [1] Allen RA, et al. Seletalisib: Characterization of a Novel, Potent, and Selective Inhibitor of PI3Kδ. J Pharmacol Exp Ther. 2017 Apr 25. pii: jpet.116.237347. DOI:10.1124/jpet.116.237347 |
| | Seletalisib Preparation Products And Raw materials |
|